The Future Of Mental Health: Psychedelic Medicine For Depression, Addiction, Trauma, And More

Mental health problems are the number one driver of indirect healthcare costs, loss of productivity, and diminished quality of life. Yet, we aren’t very successful at treating them with modern medicine.

Today on The Doctor’s Farmacy, I am excited to talk to Dr. Pamela Kryskow about the renaissance of psychedelic medicine and how these compounds are finally being recognized as powerful tools for overcoming hard-to-treat health issues like PTSD, depression, addiction, and more.

We kick off our conversation by talking about how unresolved trauma is often a core factor at the root of chronic mental health conditions. Trauma can get ‘stuck’ in the body, guarded by our nervous system in an effort to keep us safe. Dr. Kryskow explains how psychedelic medicine can help resolve deep-seated trauma and improve our sense of wellbeing and safety in the world. We talk about the different types of psychedelics, such as psilocybin, ketamine, and MDMA, and how these compounds work at the cellular and neural circuit level to trigger neuroplasticity, which is our brain’s ability to rewire itself in ways that lead to long-lasting shifts in our emotional, cognitive, and behaviors patterns.

Throughout our conversation, we discuss Dr. Kryskow’s extensive clinical experience with psychedelic-assisted therapy for the treatment of depression, PTSD, and end-of-life distress. Dr. Kryskow shares clinical trial evidence that shows a success rate of PTSD resolution of 92% in 12 weeks, whereas, in a traditional psychiatric model, the success rate is 30 to 40% over many years.

We also talk about microdosing, which is the practice of consuming very low doses of a psychedelic compound. Dr. Kryskow explains how microdosing differs from a full-dose psychedelic experience in terms of effects and intended outcomes, and how it can potentially be used as a long-term strategy for mental well-being and cognitive enhancement. We also talk about what the future of psychedelics looks like and how we can make psychedelics more scalable and accessible in a safe and responsible way. I hope you’ll tune in to learn more. 

Back to Content Library